A trial of magrolimab with chemotherapy to treat acute myeloid leukaemia and myelodysplastic syndrome

This trial looked at an immunotherapy drug called magrolimab alone or with azacitidine for acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS). Magrolimab is pronounced mah-grow-lih-mab.

It was for people with either:

• higher risk MDS who had not had treatment with chemotherapy or immunotherapy or

• AML who had not had treatment and were unable to have intensive chemotherapy

The trial was open for people to join between 2015 and 2018. The team published the results for magrolimab with azacitidine in 2023.